MedPath
FDA Approval

Silver Sulfadiazine

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Bryant Ranch Prepack
DUNS: 171714327
Effective Date
March 15, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Silver sulfadiazine(10 mg in 1 g)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Bryant Ranch Prepack

171714327

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Bryant Ranch Prepack

Bryant Ranch Prepack

Bryant Ranch Prepack

171714327

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Silver Sulfadiazine

Product Details

NDC Product Code
63629-8771
Application Number
NDA018810
Marketing Category
NDA (C73594)
Route of Administration
TOPICAL
Effective Date
September 1, 2021
Code: W46JY43EJRClass: ACTIBQuantity: 10 mg in 1 g
WATERInactive
Code: 059QF0KO0RClass: IACT
POLYOXYL 40 STEARATEInactive
Code: 13A4J4NH9IClass: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACT
STEARYL ALCOHOLInactive
Code: 2KR89I4H1YClass: IACT
ISOPROPYL MYRISTATEInactive
Code: 0RE8K4LNJSClass: IACT
SORBITAN MONOOLEATEInactive
Code: 06XEA2VD56Class: IACT
METHYLPARABENInactive
Code: A2I8C7HI9TClass: IACTQuantity: 3 mg in 1 g
PETROLATUMInactive
Code: 4T6H12BN9UClass: IACT

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

WARNINGS SECTION

WARNINGS

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis.
There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.
Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low.
The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.


© Copyright 2025. All Rights Reserved by MedPath